Question explored with the scientific record
Should I be using ramipril
Ramipril has real, hard-outcome evidence in heart failure and high vascular risk. Whether you should take it depends entirely on which of those you are.
The honest answer is that I cannot tell you without knowing your condition. The trials that matter are specific. In people with heart failure after a heart attack, ramipril cut deaths from about 23 in 100 to about 17 in 100 over roughly 15 months [1]. In high-risk patients with vascular disease but no heart failure, it reduced the combined risk of heart attack, stroke, or cardiovascular death from 17.7% to 14.1% [2]. In people 70 and older with vascular disease, major vascular events fell from 24.0% to 18.6% [3]. In diabetics with high cardiovascular risk, the composite endpoint dropped 25% [7]. That is real evidence with hard endpoints, not surrogate lab values.
| Group | Placebo risk | Ramipril risk |
|---|---|---|
| Heart failure after heart attack [1] | 22.6% died | 16.9% died |
| High vascular risk (HOPE) [2] | 17.7% | 14.1% |
| Age 70+ with vascular disease [3] | 24.0% | 18.6% |
The catch is that the benefit is not universal. Early ACE inhibition in unselected heart attack patients often did not improve survival and may have caused harm, with benefit concentrated in those who had heart damage or blocked vessels [4]. The main side effects are a dry cough, seen in about 7 in 100 users overall and higher in women [5], plus kidney changes and low blood pressure [6]. Combining ramipril with an ARB added no benefit and more harm [6].
My call: if you have heart failure, prior heart attack with reduced heart function, or established vascular disease, the evidence favors taking it. If you are being handed it for mild blood pressure alone, the case is much weaker and the burden is on whoever prescribed it. Confidence: moderate, because the trials are strong but I do not know your diagnosis.
Sources used 7
-
Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
A multicenter, randomized, double-blind trial found that initiating ramipril 2–9 days after acute myocardial infarction in patients with clinical heart failure substantially reduced all-cause mortality and improved major clinical outcomes over ~15 months, with good tolerability.
DOI: 10.1016/0140-6736(93)92693-n -
The anti-ischemic potential of angiotensin-converting enzyme inhibition: Insights from the heart outcomes prevention evaluation trial
ACE inhibition with ramipril 10 mg daily reduced the composite of myocardial infarction, stroke, or cardiovascular death in high-risk patients without left ventricular dysfunction, indicating anti-ischemic and vascular-protective benefits beyond modest blood pressure lowering.
DOI: 10.1002/clc.4960230704 -
Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients
This study evaluates the efficacy and safety of long-term ramipril therapy in reducing major cardiovascular events among elderly patients with vascular disease, demonstrating significant benefits compared to placebo.
DOI: 10.1093/eurheartj/ehm017 -
Inhibition of ACE/kininase-II, acute myocardial infarction, and survival
A comprehensive review of randomized ACE inhibitor trials after acute myocardial infarction, showing that early ACE inhibition in unselected patients often does not improve survival and may cause harm, whereas benefits may emerge in selected subgroups (e.g., with left ventricula…
DOI: 10.1093/cvr/28.2.190 -
ACE INHIBITORS
Comparative evaluation of ACE inhibitors in hypertensive patients shows overall 7% cough incidence with different cough rates across lisinopril (8.82%), ramipril (6.89%), and perindopril (5.4%), and higher incidence in women.
DOI: 10.29309/tpmj/2016.23.09.1712 -
On Target to Dual Block RAS?
A comprehensive review of dual blockade of the renin-angiotensin system (ARB + ACE inhibitor) in high-risk cardiovascular patients, highlighting ONTARGET findings that combining telmisartan and ramipril did not improve cardiovascular outcomes beyond single agents and was associa…
DOI: 10.1177/0003319708329799 -
Optimizing the diabetic formulary: beyond aspirin and insulin
A comprehensive 2002 JACC review that argues for expanding diabetic cardiovascular risk management beyond aspirin and insulin, synthesizing evidence from major trials to advocate broader use of ACE inhibitors/ARBs, statins, antiplatelet therapies, and related strategies to reduc…
DOI: 10.1016/s0735-1097(02)02006-5